Table S1-List of primers used for qPCR

Gene Name	Sense Sequence	Antisense sequence
18S rRNA	CGGCGACGACCCATTCGAAC	GAATCGAACCCTGATTCCCCGTC
XBP-1	CCTTGTAGTTGAGAACCAGG	GGGGCTTGGTATATATGTGG
ERO1Lβ	ATGCTTTGCTGGTGCTCT	CTTCATCAGTGGGTACAATCATTTC
ATF6α	TCGAAGGGATCACCTGCTGTT	TCAGGGATGGTGCTGACAAC
PDIA4	TACAACGGCCCACGAGAAAA	CTCAGGTTGTTAGCGGCATC
GADD153	GGAAACAGAGTGGTCATTCCC	CTGCTTGAGCCGTTCATTCTC

Table S2-List of antibodies and the dilutions

Antibody	Dilution
For Immunoblotting	
ATF6α	1:500
peIF2α	1:1000
eIF2α	1:1000
BiP	1:10,000
GAPDH	1:5000
For Immunohistochemistry	
ATF6α	1:100
BiP	1:200
PDI	1:100
For immunofluorescence	
ATF6α	1:200
Calreticulin	1:300
Cleaved Caspase-3	1:300
GM-130	1:3500
Active Bax	1:100
Alexa Fluor 488	1:800-1:1000
Alexa Fluor 555	1:1000

		GSK		STF	
Cell Lines	Fa (%). cisplatin alone	Fa (%)	CI	Fa (%)	CI
U2OS	1.0±0.0	1.±0.0	>1	1.0±0.0	>1
	55.3±0.6	55.3±3.2	0.65	57.3±4.7	0.75
	66.7±9.1	66.3±9.5	0.91	65.0±7.0	>1
	90.7±11.0	90.5±12.1	0.83	90.3±13.3	0.90
143b	1.1±0.14	1±0.0	>1	1±0.0	>1
	18.65±0.49	19.35±3.3	>1	14.6±3.4	>1
	82.7±0.00	81.7±0.4	0.76	83.8±1.4	0.79
	86±1.41	87±0.0	>1	86.75±0.5	>1
hFOB	1.5±0.71	1±0.0	>1	3±1.4	>1
	32.2±1.13	26.85±1.5	1.00	24.55±1.1	>1
	52.95±4.60	40.25±12.5	>1	38.8±10.5	>1
	76.7±0.42	66.6±15.0	>1	65.7±13.7	>1

		GSK		STF	
Cell Lines	Fa (%). irinotecan alone	Fa (%)	CI	Fa (%)	CI
U2OS	8.5±10.5	9.85±12.5	>1	18.5±24.7	>1
	11±14.2	13.5±17.7	>1	23.7±24.6	>1
	59±9.9	57.7±10.9	0.84	59.1±40.9	>1
	82.4±3.1	86.2±4.9	0.83	80.6±22.5	>1
143b	35.7±15.5	32.95±18.0	>1	38.8±19.7	0.99
	63.5±20.8	59.75±21.3	>1	63.4±12.5	0.89
	72.0±11.4	70.1±8.9	>1	70.4±4.8	>1
	87.5±0.4	84.75±1.1	>1	87±49.5	0.86
hFOB	19.5±4.9	21.1±1.3	>1	21.6±12.4	>1
	36.5±0.8	37.8±2.0	0.80	43.7±2.5	0.54
	44.3±2.2	44.745±0.3	0.87	51.2±4.5	0.55
	49±1.6	50.6±0.7	>1	56.8±3.2	0.40

Tables S3 and S4-Combination screening for drug synergy in osteosarcoma. Table with select Fa values and CI of different combinations cisplatin or irinotecan with GSK or STF. Synergy calculations were done using the Chou and Talalay combination index (CI), based on the median-effect and mass-action principles.